Summary & Overview
HCPCS G9416: Tdap Vaccine Given Between Ages 10 and 13
HCPCS Level II code G9416 documents administration of a single tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) given on or between a patient’s 10th and 13th birthdays. This preventive immunization code matters nationally as part of adolescent vaccine coverage and school-entry immunization tracking; proper coding supports public health surveillance and payer policy alignment.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise code definition and clinical context for adolescent Tdap vaccination, an overview of where the service is typically provided, and note of common ancillary billing elements when available. The publication outlines what to expect in payer coverage patterns and documentation priorities, plus where to find related coding guidance.
This national summary targets clinical coders, billing teams, and policy analysts seeking a clear reference for G9416, situating the code within preventive care delivery for adolescents and highlighting the code’s role in immunization reporting and reimbursement workflows.
Billing Code Overview
HCPCS Level II code G9416 indicates that a patient received one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) on or between the patient's 10th and 13th birthdays. This service represents administration of a routine adolescent immunization.
-
Service type: Vaccine administration for adolescent
Tdapbooster -
Typical site of service: Outpatient clinic, pediatrician or family medicine office, school-based health center, or other ambulatory care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 12-year-old adolescent presents to a pediatric clinic for routine immunizations as part of school entry requirements and adolescent preventive care. The patient’s immunization record is reviewed, and documentation confirms no prior tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) between ages 10 and 13. The clinician verifies immunization history, obtains informed consent from the parent/guardian, screens for contraindications (e.g., severe allergic reaction to a prior dose or vaccine component, acute moderate or severe illness), and administers a single Tdap intramuscular injection in the deltoid. Post-vaccination observation for 15 minutes is performed for syncope risk. Vaccine lot number, manufacturer, administration site, and clinician information are documented in the medical record and the state immunization registry. The service is billed using HCPCS Level II code G9416 to report that one Tdap vaccine was given on or between the patient’s 10th and 13th birthdays. Typical sites of service include pediatrician offices, family medicine clinics, school-based health centers, and community health clinics. Typical modifiers that may accompany billing for this service include those indicating unusual procedural circumstances, anesthesia, or third-party payment arrangements when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|